© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Most Phase I study participants responded to the experimental immunotherapy.
Long-term follow-up from ZUMA-1 trial shows patients remain cancer-free for up to two years.
Findings from the JULIET trial support expanded Food and Drug Administration approval of customized T cells.
Venclexta combination therapy clears leukemia in blood and bone marrow, recent studies show.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
